Literature DB >> 12324751

Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII.

Jack D Bui1, George D Despotis, Elbert P Trulock, G Alexander Patterson, Lawrence T Goodnough.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12324751     DOI： 10.1067/mtc.2002.126038

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN： 0022-5223            Impact factor:   5.209


× No keyword cloud information.
  16 in total

1.  High mortality associated with intracardiac and intrapulmonary thromboses after cardiopulmonary bypass.

Authors:  Satoru Ogawa; James E Richardson; Tetsuro Sakai; Masahiro Ide; Kenichi A Tanaka
Journal:  J Anesth       Date:  2011-10-19       Impact factor: 2.078

Review 2.  Recombinant factor VIIa: a review on its clinical use.

Authors:  Massimo Franchini
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

3.  Emicizumab should be prescribed independent of immune tolerance induction.

Authors:  Sandra Le Quellec; Claude Negrier
Journal:  Blood Adv       Date:  2018-10-23

4.  Novoseven use in a non-cardiac pediatric ECMO patient with uncontrolled bleeding.

Authors:  Thomas J Preston; Vincent F Olshove; Onsy Ayad; Kathleen K Nicol; Jeffrey B Riley
Journal:  J Extra Corpor Technol       Date:  2008-06

5.  Safety and efficiency of recombinant activated factor VII in postcardiotomy massive hemorrhage.

Authors:  Yoan Lamarche; Philippe Demers; Nancy C Poirier; Danielle Robitaille; Raymond Cartier
Journal:  Can J Cardiol       Date:  2007-08       Impact factor: 5.223

6.  Use of recombinant factor VIIa (NovoSeven) in pediatric cardiac surgery.

Authors:  Scott D Niles; Harold M Burkhart; David A Duffey; Keri Buhrman; Jeffrey Burzynski; David W Holt
Journal:  J Extra Corpor Technol       Date:  2008-12

Review 7.  Neonatal ECMO.

Authors:  Cornelia Heleen Van Ommen; Cindy E Neunert; Meera B Chitlur
Journal:  Front Med (Lausanne)       Date:  2018-10-25

8.  Use of activated recombinant factor VII for severe coagulopathy post ventricular assist device or orthotopic heart transplant.

Authors:  Manish J Gandhi; Richard A Pierce; Lini Zhang; Marc R Moon; George J Despotis; Nader Moazami
Journal:  J Cardiothorac Surg       Date:  2007-07-06       Impact factor: 1.637

Review 9.  Recombinant activated factor VIIa for the treatment of bleeding in major abdominal surgery including vascular and urological surgery: a review and meta-analysis of published data.

Authors:  Christian von Heymann; Sven Jonas; Claudia Spies; Klaus-Dieter Wernecke; Sabine Ziemer; Detlev Janssen; Jürgen Koscielny
Journal:  Crit Care       Date:  2008-02-15       Impact factor: 9.097

Review 10.  Recombinant factor VIIa for uncontrollable bleeding in patients with extracorporeal membrane oxygenation: report on 15 cases and literature review.

Authors:  Xavier Repessé; Siu Ming Au; Nicolas Bréchot; Jean-Louis Trouillet; Pascal Leprince; Jean Chastre; Alain Combes; Charles-Edouard Luyt
Journal:  Crit Care       Date:  2013-03-25       Impact factor: 9.097
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.